Piq.Ax
Piq A is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of medical products and services.
Business. Piq A is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of medical products and services.
Analyst recommendations
1 analysts · consensus SellAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Piq A is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of medical products and services.
Piq A maintains a strong liquidity position, with a current ratio of 9.39, indicating a high ability to meet short-term obligations. The company holds significant cash and equivalents of AUD 9,416,590, which is a substantial portion of its total assets of AUD 14,781,540. The debt-to-equity ratio is low at 0.02, suggesting minimal reliance on debt financing and a conservative capital structure.
The company's profitability is currently negative, with a return on equity of -61.61% and a return on assets of -54.9%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income and net income are both negative, at -AUD 8,266,680 and -AUD 8,114,800, respectively, highlighting the need for operational improvements or cost reductions.
Piq A's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no specific geographic breakdown provided. This lack of diversification may expose the company to higher risks if its primary market experiences downturns. The absence of detailed segment or geographic data limits the ability to assess the company's exposure to different markets.
The company's growth trajectory is currently negative, with a declining revenue trend and negative operating and net income. The operating cash flow is also negative at -AUD 6,604,340, and the free cash flow is -AUD 7,561,440, indicating that the company is not generating sufficient cash from operations to sustain or grow its business. The capital expenditure is minimal at -AUD 29,650, suggesting limited investment in long-term growth initiatives.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and high cash reserves contribute to its strong liquidity position. However, the negative profitability metrics and declining cash flows suggest potential operational and financial risks that could affect the company's long-term sustainability.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The analyst estimates show a mean recommendation of 4.00, with one sell rating and no strong buy or buy ratings, reflecting a cautious outlook from the investment community.
- Piq A has a strong liquidity position with a current ratio of 9.39 and significant cash reserves.
- The company is currently unprofitable, with a return on equity of -61.61% and a return on assets of -54.9%.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is experiencing negative cash flows and declining profitability, indicating operational challenges.
- Analysts have a cautious outlook, with one sell rating and no strong buy or buy ratings.
- "margin_outlook_rationale": "The company's negative operating and net income suggest declining margins, driven by high operating costs and low revenue growth.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PIQ.AX Market data — financials · 2026-05-28
- Proteomics International Laboratories Ltd Market data — analyst estimates · 2026-05-28